News

The PHenomenal Impact Fund for Global PH Research is accepting research proposals, according to a press release. On its fifth year, Team PHenomenal Hope’s research fund will award up to $50,000 for 12 months for proposals that focus on new concepts in pulmonary hypertension (PH) that have…

Enrollment is now complete in REBUILD, a Phase 3 clinical trial evaluating INOpulse, an investigational treatment for people with pulmonary fibrosis (PF) who are at risk of developing pulmonary hypertension (PH). According to the therapy’s developer, Bellerophon Therapeutics, the trial’s enrollment was completed earlier than expected. As…

Pulmonary hypertension (PH) is estimated to be highly prevalent among people with a history of tuberculosis (TB) who successfully completed treatment, a study in South Africa reports. Further, individuals who were treated for TB more than once had a higher risk of developing PH compared with those who…

Treatment with phosphodiesterase-5 (PDE5) inhibitors can improve blood flow parameters and exercise capacity in people with pulmonary hypertension (PH), according to a new analysis of clinical trial data. “The study found that the reduction in mean PAP [peripheral arterial pressure] was significantly greater in patients receiving PDE5 inhibitors,” the…

The U.S. Food and Drug Administration (FDA) has approved the third generation of Genosyl, Vero Biotech‘s tankless system for nitric oxide delivery, for use as part of care for newborns with pulmonary hypertension. “The continuous innovation of the GENOSYL Delivery System represents our commitment to neonatal intensive care…

The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after an episode of acute pulmonary embolism (PE) is likely underestimated, a study suggests. This occurs despite the high frequency of symptoms consistent with CTEPH, underscoring that an appropriate diagnostic work-up of CTEPH is rarely undertaken. The study, “CTEPH: a…

Low activity levels in a small RNA molecule called miR126 may be implicated in vascular remodeling — a hallmark feature of pulmonary hypertension (PH) — in the lungs of chronic obstructive pulmonary disease (COPD) patients regardless of whether or not they also have PH, a study reported. This…

People with pulmonary hypertension (PH) who had elevated blood levels of the trimethylamine N-oxide (TMAO) molecule were at a five times greater risk of a poor prognosis than patients who didn’t have high levels, according to a recent study. High levels of this gut-derived metabolite were generally linked to…

Two new biomarkers to assess pulmonary arterial hypertension (PAH) were discovered through large-scale analysis of gene activity profiles using computer software, a study reported. These biomarkers, the activity of the genes PNISR and HNRNPH1, may help diagnose PAH, monitor its progression, or measure responses to therapy. They also may highlight…

People with pulmonary arterial hypertension (PAH) may lack some key vitamins and minerals their bodies need daily to stay healthy, which may lessen their vitality, according to a small study from the Netherlands. Besides the known lack of vitamin D and iron, researchers observed lower than recommended levels of…

Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments in research, care, and treatment related to pulmonary hypertension (PH). We hope to continue to be a resource for the PH community in the coming year. Here is a…

Increasing the levels of the Tex261 protein — either as a preventive or therapeutic approach — eased the symptoms of pulmonary arterial hypertension (PAH) in a rat model of the disease, a new study shows. These benefits were seen after the scientists had found that PAH development in…